Eysuvis is a Ophthalmic Suspension/ Drops in the Human Prescription Drug category. It is labeled and distributed by Kala Pharmaceuticals, Inc.. The primary component is Loteprednol Etabonate.
Product ID | 71571-333_3e42627b-9893-4de3-821b-9a0ce8aeebf8 |
NDC | 71571-333 |
Product Type | Human Prescription Drug |
Proprietary Name | Eysuvis |
Generic Name | Loteprednol Etabonate |
Dosage Form | Suspension/ Drops |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2020-11-18 |
Marketing Category | NDA / NDA |
Application Number | NDA210933 |
Labeler Name | Kala Pharmaceuticals, Inc. |
Substance Name | LOTEPREDNOL ETABONATE |
Active Ingredient Strength | 3 mg/mL |
Pharm Classes | Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2020-11-18 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
71571-333 | Eysuvis | loteprednol etabonate |
24208-353 | Alrex | loteprednol etabonate |
71571-121 | Inveltys | loteprednol etabonate |
24208-299 | LOTEMAX | loteprednol etabonate |
24208-443 | Lotemax | loteprednol etabonate |
24208-503 | LOTEMAX | loteprednol etabonate |
24208-507 | Lotemax SM | loteprednol etabonate |
17478-830 | Loteprednol Etabonate | Loteprednol Etabonate |
24208-508 | Loteprednol Etabonate | loteprednol etabonate |
50383-265 | Loteprednol Etabonate | Loteprednol Etabonate |
62756-232 | Loteprednol Etabonate | Loteprednol Etabonate |
68682-299 | Loteprednol Etabonate | loteprednol etabonate |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
EYSUVIS 90126591 not registered Live/Pending |
Kala Pharmaceuticals, Inc. 2020-08-20 |
EYSUVIS 90126587 not registered Live/Pending |
Kala Pharmaceuticals, Inc. 2020-08-20 |
EYSUVIS 88708748 not registered Live/Pending |
Kala Pharmaceuticals, Inc. 2019-11-27 |
EYSUVIS 88708726 not registered Live/Pending |
Kala Pharmaceuticals, Inc. 2019-11-27 |
EYSUVIS 87694659 not registered Live/Pending |
Kala Pharmaceuticals, Inc. 2017-11-22 |